Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 2;28(3):1449.
doi: 10.3390/molecules28031449.

Co-Encapsulation of Drugs for Topical Application-A Review

Janaína Artem Ataide  1   2 , Julia Cedran Coco  1 , Érica Mendes Dos Santos  1 , Viviane Beraldo-Araujo  1 , Jéssica Ribeiro Alves Silva  1 , Karine Cappuccio de Castro  3 , André Moreni Lopes  1 , Nina Filipczak  2 , Satya Siva Kishan Yalamarty  2 , Vladimir P Torchilin  2   4 , Priscila Gava Mazzola  1
Affiliations
Review

Co-Encapsulation of Drugs for Topical Application-A Review

Janaína Artem Ataide et al. Molecules. .

Abstract

Achieving the best possible outcome for the therapy is the main goal of a medicine. Therefore, nanocarriers and co-delivery strategies were invented to meet this need, as they can benefit many diseases. This approach was applied specifically for cancer treatment, with some success. However, these strategies may benefit many other clinical issues. Skin is the largest and most exposed organ of the human body, with physiological and psychological properties. Due to its exposition and importance, it is not difficult to understand how many skin diseases may impact on patients' lives, representing an important burden for society. Thus, this review aims to summarize the state of the art in research concerning nanocarriers and co-delivery strategies for topical agents' applications targeting skin diseases. The challenge for the medicine of the future is to deliver the drug with spatial and temporal control. Therefore, the co-encapsulation of drugs and the appropriate form of administration for them are so important and remain as unmet needs.

Keywords: co-encapsulation; nanoparticles; skin barrier; topical delivery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of two ways of drug delivery through the skin (created by Biorender).
Figure 2
Figure 2
Schematic mechanisms for skin permeation of active components from nanoparticles [29].
See this image and copyright information in PMC

References

    1. Hay R.J., Augustin M., Griffiths C.E.M., Sterry W., Board of the International League of Dermatological Societies. the Grand Challenges Consultation groups The global challenge for skin health. Br. J. Dermatol. 2015;172:1469–1472. doi: 10.1111/bjd.13854. - DOI - PubMed
    1. Romanhole R.C., Fava A.L.M., Tundisi L.L., Macedo L.M.d., Santos É.M.d., Ataide J.A., Mazzola P.G. Unplanned absorption of sunscreen ingredients: Impact of formulation and evaluation methods. Int. J. Pharm. 2020;591:120013. doi: 10.1016/j.ijpharm.2020.120013. - DOI - PubMed
    1. Richard M.A., Paul C., Nijsten T., Gisondi P., Salavastru C., Taieb C., Trakatelli M., Puig L., Stratigos A., EADV Burden of Skin Diseases Project Team Prevalence of most common skin diseases in Europe: A population-based study. J. Eur. Acad. Dermatol. Venereol. 2022;36:1088–1096. doi: 10.1111/jdv.18050. - DOI - PMC - PubMed
    1. Flohr C., Hay R. Putting the burden of skin diseases on the global map. Br. J. Dermatol. 2021;184:189–190. doi: 10.1111/bjd.19704. - DOI - PubMed
    1. Cullen J.K., Simmons J.L., Parsons P.G., Boyle G.M. Topical treatments for skin cancer. Adv. Drug Deliv. Rev. 2020;153:54–64. doi: 10.1016/j.addr.2019.11.002. - DOI - PubMed